Dolutegravir and raltegravir cause changes to fat cells
Weight gain after switching to integrase inhibitor treatment is small in Dutch and Swiss cohorts
ADVANCE study shows high frequency of major weight gain in women receiving dolutegravir with TAF
Weight gain on HIV treatment: drug combinations, not single drugs, need to be focus of quest for cause
Weight gain on HIV treatment: more common with newer drugs, low CD4 counts
Women with HIV not at higher risk of blood pressure disorders in pregnancy
Switching to TAF-based PrEP improves kidney and bone markers – but does it raise cardiovascular risk?
Do integrase inhibitors increase the risk of diabetes?
ADVANCE trial shows dolutegravir is highly effective in South Africa
